XORTX Announces Publication of Key Research in ADPKD
22 4월 2024 - 8:00PM
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ:
XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a
late-stage clinical pharmaceutical company focused on developing
innovative therapies to treat progressive kidney disease, is
pleased to announce a research paper titled
“Raising serum
uric acid with a uricase inhibitor worsens PKD in rat and mouse
models" has been accepted for publication in the
peer-reviewed American Journal of Physiology-Renal Physiology and
published online April 19, 2024.
This study reports health consequences
associated with increasing serum uric acid (“SUA”) in mice or rat
models of Autosomal Dominant Polycystic Kidney Disease (“ADPKD”),
specifically the effects of increasing SUA on cyst growth and
kidney size. Cyst genesis and cyst growth (together “cyst index”)
and their rates of change are important indicators of disease
progression and are correlated with declining filtering capacity
and end stage renal disease (“ESRD”). This study shows, for the
first time, that chronically increased SUA can significantly
increase cyst index and increase kidney size in ADPKD.
According to the study’s findings, saturating
concentrations of SUA contributing to “crystal injury” were not
necessary to negatively alter both structure and function of the
ADPKD kidney. Moderately high SUA concentrations were also found to
be associated with an increased inflammatory state (cytokine
profile) in both serum and kidney tissue. Independent of the
modifying effects of chronically increased SUA, a fundamental new
discovery from this study was that over expression of xanthine
oxidase (“XO”) in kidney tissue was present, suggesting aberrant
purine metabolism may be present in ADPKD and suggesting a possible
role of XO in disease progression.
When considered together, SUA above the normal
range and overexpression of XO, especially in the location of
cysts, in an ADPKD kidney represents a strong impetus for the use
of XO inhibition to attenuate this newly described mechanism of
injury. Inhibition of XO using XORLO™, XORTX’s proprietary
formulation of oxypurinol, substantially lowered uric acid
concentrations, attenuated the effects of chronically increased SUA
on cyst index and kidney size in the RC/RC mouse model of ADPKD in
this study.
Dr. Allen Davidoff, CEO of XORTX, stated, “We
are pleased to have supported this pioneering research in
polycystic kidney disease by Dr. Charles Edelstein of the
University of Colorado. Identifying for the first time that
increased serum uric acid and possibly overexpression of xanthine
oxidase in the ADPKD kidney can accelerate disease progression has
substantial implications. This study provides important novel
insight into one modifying factor that has the potential to
accelerate ADPKD progression. In human ADPKD, kidney size and
declining kidney filtering capacity are correlated and are key
indicators of disease progression and prognosis. Identifying any
modifiable factor that explains variable outcomes in individuals
with ADPKD is a seminal step forward in our understanding of this
disease. XORLOTM was shown to attenuate this effect. In concept,
XORLOTM should be capable of attenuating both of these modifiable
factors. These mechanistic studies are important for the planning
of future clinical studies of xanthine oxidase inhibition in
patients with ADPKD.”
About ADPKD
ADPKD is a rare
disease that affects more that 10 million individuals worldwide.1,2
ADPKD is typically diagnosed based upon expansion of fluid-filled
cysts in the kidneys. Over time, the increasing number and size of
cysts can contribute to structural and functional changes to
kidneys and is frequently accompanied by chronic pain which is a
common problem for patients with ADPKD.3 Expansion of cysts is
thought to compress healthy functioning tissue surrounding the
cysts and contribute to further loss of kidney function, fibrosis,
impaired nutrient exchange and impaired kidney function,
accompanied later by end-stage renal disease.1 For individuals with
progressing ADPKD, treatment recommendations include
anti-hypertensive treatment, dietary restrictions, and, for a
limited percentage of suitable patients, pharmacotherapy.4 New,
more broadly applicable therapies to effectively slow decline of
kidney function in ADPKD are needed.
References:
- Wiley C., Kamat S., Stelhorn R.,
Blais J., Analysis of nationwide date to determine the incidence
and diagnosis of autosomal dominant polycystic kidney disease in
the USA, Kidney Disease, 5(2): 107-117, 2019
- Bergmann C., Guay-Woodford L.M.,
Harris P.C., Horie S., Peters D.J., Torres V.E., Polycystic Kidney
Disease, Nat Rev Dis Primers. 4(1): 50, 2018
-
https://pkdcure.org/living-with-pkd/chronic-pain-management/
- Gimpel C., Bermann C., Bockenhauer
D., et al., International consensus statement of the diagnosis and
management of autosomal dominant polycystic kidney disease in
children and young people, Nat Rev Nephrol 15(11):713-726,
2019
Communications and Social Media
Engagements
Further to the Company’s press release of April
8, 2024, XORTX continues its participation in important healthcare
and investor conferences, including most recently the Noble Capital
Markets Emerging Growth Virtual Healthcare Equity Conference and
the CEM Scottsdale Capital Event. Additional information on how to
listen to webcast presentations, where available, will be provided
at a later date. The Company is also augmenting investor awareness
through the engagement of marketing and communication consultants,
including:
- LFG Equities has been engaged to
provide marketing consulting and market communications services,
for a fee of US$50,000 for a one-month period. The LFG Equities
engagement can be extended by mutual consent and can be terminated
by XORTX upon 10 days’ notice.
- IRPUB has been engaged to provide a
XORTX awareness campaign for a fee of US$40,000 for a term of four
months. The IRPUB engagement can be extended by mutual consent and
can be terminated by XORTX at that time.
- FeMax Publishing and Consulting
Ltd. has been engaged to analyze and assess European communications
and investor contact outreach in Europe. The term of the contract
is for 12 months with the assessment services at a monthly fee of
€3,500 and the European Awareness campaign at a monthly fee of
€8,500. The FeMax Publishing and Consulting engagement can be
extended by mutual consent.
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with two
clinically advanced products in development: 1) our lead, XRx-008
program for ADPKD is in preparation to conduct a single
registration trial – XRX-OXY-201, that is eligible for accelerated
approval; and 2) our secondary program in XRx-101 for acute kidney
and other acute organ injury associated with Coronavirus / COVID-19
infection. In addition, XRx-225 is a pre-clinical stage program for
Type 2 Diabetic Nephropathy. XORTX is working to advance its
clinical development stage products that target aberrant purine
metabolism and xanthine oxidase to decrease or inhibit production
of uric acid. At XORTX, we are dedicated to developing medications
to improve the quality of life and future health of patients.
Additional information on XORTX is available at www.xortx.com.
For more information, please contact:
Allen Davidoff, CEO |
Nick Rigopulos, Director of Communications |
adavidoff@xortx.com or +1 403
455 7727 |
nick@alpineequityadv.com or +1 617 901 0785 |
|
|
Kim Golodetz, LHA Investor
Relations |
|
kgolodetz@lhai.com or +1 212
838 3777 |
|
Neither the TSX Venture Exchange nor Nasdaq has
approved or disapproved the contents of this news release. No stock
exchange, securities commission or other regulatory authority has
approved or disapproved the information contained herein.
Forward Looking Statements
This press release
contains express or implied forward-looking statements pursuant to
applicable securities laws. These forward-looking statements and
their implications are based on the current expectations of the
management of XORTX only, and are subject to a number of factors
and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
Except as otherwise required by applicable law and stock exchange
rules, XORTX undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. More detailed information about the risks and
uncertainties affecting XORTX is contained under the heading “Risk
Factors” in XORTX’s Annual Report on Form 20-F filed with the SEC,
which is available on the SEC's website, www.sec.gov (including any
documents forming a part thereof or incorporated by reference
therein), as well as in our reports, public disclosure documents
and other filings with the securities commissions and other
regulatory bodies in Canada, which are available on
www.sedarplus.ca.
Xortx Therapeutics (TSXV:XRTX)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Xortx Therapeutics (TSXV:XRTX)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024